<DOC>
	<DOCNO>NCT01231542</DOCNO>
	<brief_summary>This study phase I , open label , two arm , fix sequence crossover study investigate effect rifampin rifabutin steady state pharmacokinetics ( PK ) GSK1349572 safety tolerability GSK1349572 rifamycin co-administration . Subjects enrol Arm 1 receive GSK1349572 50 mg daily 7 day , GSK1348572 50 mg twice daily 7 day , GSK1349572 50 mg twice daily combination rifampin 600 mg daily 14 day . Subjects Arm 2 receive GSK1349572 50 mg daily 7 day GSK1349572 50 mg daily combination rifabutin 300 mg daily 14 day . Serial PK sampling complete follow last dose treatment . Safety tolerability assess throughout study assessment adverse event ( AEs ) , clinical laboratory test . This study conduct one center US healthy adult male female subject .</brief_summary>
	<brief_title>Phase 1 , Open Label , Two Arm , Fixed Sequence Study Evaluate Effect Rifampin Rifabutin GSK1349572 Pharmacokinetics Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test electrocardiogram ( ECG ) . Within 28 few day prior enrollment , complete blood count differential , comprehensive serum chemistry profile , human immunodeficiency virus ( HIV ) antibody test , Hepatitis C antibody test perform , follow laboratory value : Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin less equal upper limit normal ( ULN ) Hemoglobin great equal 12.0 men , great equal to11.0 woman Serum creatinine less equal to1.5 mg/dL Platelet count great equal 125,000 /cu mm Absolute neutrophil count great equal 1250 /cu mm HIV antibody test negative Hepatitis C antibody negative Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list protocol time period screen dose study drug sufficiently minimize risk pregnancy point . Female subject must also agree use contraception throughout study two week last dose study medication . Body weight range 53100 kg ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day 5 halflives ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . Any illicit drug use within precede 2 month . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , peptic ulceration , inflammatory bowel disease pancreatitis exclude . History/evidence clinically significant pulmonary disease . History significant renal hepatobiliary disease . History severe serious psychiatric disease ever require hospitalization , history suicidal ideation suicidal attempt , undergo psychiatric treatment . Site investigator suspicion active tuberculosis ( TB ) . History Gilbert 's disease . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>dolutegravir</keyword>
	<keyword>integrase</keyword>
	<keyword>rifabutin</keyword>
	<keyword>rifampin</keyword>
</DOC>